Search results
Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
Zacks via Yahoo Finance· 13 hours agoNumerous recent approvals and the expected launch of many additional indications, including in...
Merck stopped a clinical trial for its experimental skin cancer drug after a high rate of side...
Quartz· 1 day agoThe study was testing whether a combination of the company’s flagship cancer drug Keytruda and its...
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma...
Benzinga· 1 day agoThe trial evaluates the investigational coformulation of vibostolimab and Keytruda (pembrolizumab)...
Merck stops testing combo drug for skin cancer as more patients discontinue
AOL· 2 days agoThis is the latest setback for the experimental drug, vibostolimab, and the related promising new class of immunotherapies called anti-TIGIT. Merck was testing vibostolimab ...
Merck halts research on combo drug for skin cancer
Becker’s Hospital Review· 2 days agoMerck will stop testing an experimental combination treatment for skin cancer patients in a late-stage study, the drugmaker said May 13. Merck was evaluating the use of the ...
Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study
Morningstar· 2 days agoMerck & Co. has ended part of a late-stage study of a co-formulation of its blockbuster cancer drug Keytruda in certain skin-
Moderna Stock Rebounds From Its RSV Vaccine Fallout — Is It A Buy, Again?
Investor's Business Daily· 11 hours agoMeanwhile, Moderna is expanding its efforts in cancer treatment. The company is partnered with Merck...
...Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive......
Benzinga· 21 hours agoOSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that
PDS Biotechnology Corp. (NASDAQ:PDSB) Uses Cancer Immunotherapy to Infiltrate and Disable Tumors...
The Wall Street Transcript· 20 hours agoDr. Frank Bedu-Addo has served as president and CEO of PDS Biotechnology...veteran biotech executive...
Merck stops skin cancer combination therapy testing in late-stage study
Reuters· 2 days ago, opens new tab has discontinued testing a combination of an experimental antibody-based drug and...
